Free Trial
CVE:RX

BioSyent (RX) Stock Price, News & Analysis

C$9.00
0.00 (0.00%)
(As of 05/21/2024 05:33 PM ET)
Today's Range
C$8.88
C$9.00
50-Day Range
C$8.24
C$9.00
52-Week Range
C$7.03
C$9.26
Volume
27,324 shs
Average Volume
6,279 shs
Market Capitalization
C$104.31 million
P/E Ratio
16.98
Dividend Yield
2.00%
Price Target
N/A
RX stock logo

About BioSyent Stock (CVE:RX)

BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; Combogesic to manage mild to moderate acute pain and reduction of fever in adults; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. BioSyent Inc. was founded in 2006 and is headquartered in Mississauga, Canada.

RX Stock Price History

RX Stock News Headlines

BioSyent (CVE:RX) Has Affirmed Its Dividend Of CA$0.045
BioSyent (RX) Set to Announce Quarterly Earnings on Thursday
BioSyent Named to 2024 TSX Venture 50
RX:CA BioSyent Inc.
BioSyent Declares First Quarter 2024 Dividend
Bloom Burton Believes Biosyent (RX) Won’t Stop Here
BioSyent Releases Q3 and YTD 2023 Financial Results
BioSyent Declares Fourth Quarter 2023 Dividend
Closing Bell: Biosyent Inc flat on Tuesday (RX)
Closing Bell: Biosyent Inc flat on Wednesday (RX)
See More Headlines
Receive RX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioSyent and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/13/2024
Today
5/22/2024
Next Earnings (Estimated)
8/27/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
C$6.46 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$31.59 million
Cash Flow
C$2.93 per share
Book Value
C$2.96 per share

Miscellaneous

Free Float
N/A
Market Cap
C$104.31 million
Optionable
Not Optionable
Beta
0.93
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

RX Stock Analysis - Frequently Asked Questions

How have RX shares performed in 2024?

BioSyent's stock was trading at C$9.22 on January 1st, 2024. Since then, RX shares have decreased by 2.4% and is now trading at C$9.00.
View the best growth stocks for 2024 here
.

When is BioSyent's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 27th 2024.
View our RX earnings forecast
.

How were BioSyent's earnings last quarter?

BioSyent Inc. (CVE:RX) announced its quarterly earnings data on Wednesday, March, 13th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.17 by $0.05. The firm had revenue of $8.27 million for the quarter, compared to analyst estimates of $8.80 million. BioSyent had a net margin of 20.45% and a trailing twelve-month return on equity of 18.97%.

Is BioSyent a good dividend stock?

BioSyent (CVE:RX) pays an annual dividend of C$0.18 per share and currently has a dividend yield of 2.12%. The dividend payout ratio is 33.96%. This payout ratio is at a healthy, sustainable level, below 75%.

What other stocks do shareholders of BioSyent own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioSyent investors own include Aurora Cannabis (ACB), Canadian National Railway (CNR), Bank of Nova Scotia (BNS), Cross Timbers Royalty Trust (CRT), Dollarama (DOL), Enbridge (ENB), Gilead Sciences (GILD), National Bank of Canada (NA) and Air Canada (AC).

How do I buy shares of BioSyent?

Shares of RX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (CVE:RX) was last updated on 5/22/2024 by MarketBeat.com Staff

From Our Partners